[Romiplostim (Nplate) and eltrombopag (Revolade) for the treatment of immune thrombocytopenic purpura]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000709
Catalan, English
Authors' objectives:
To assess the efficacy, safety and efficiency of romiplostin and eltrombopag compared to any other alternative treatment, including placebo, in the treatment of adult chronic ITP patients.
Authors' recommendations:
Romiplostim and eltrombopag transitorily increase platelet counts and decrease the need for concomittant treatments compared to placebo in chronic ITP patients who have received at least one previous treatment. There are no consistent data showing that these two drugs reduce the risk of bleeding in this same population. Both drugs are well-tolerated but their administration has been associated to potentially serious adverse events with increased reticuline, thrombotic episodes and malignant blood disorders as well as rebound thrombocytopenia and risk of bleeding episodes once the treatment is discontinued, which require further studies. Until such time as new data on long-term safety, the use of both drugs should be restricted for patients with fractory ITP or those who present an intolerance to the standard treatment. There are no studies comparing the use of romisplotim with eltrombopag, and the choosing of one drug over the other should be based on patient characteristics.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/romiplostim_eltrombopag_pti_aiaqs2010ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Hydrazines
- Purpura, Thrombocytopenic, Idiopathic
- Pyrazoles
- Receptors, Fc
- Recombinant Fusion Proteins
- Spain
- Thrombopoietin
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.